Real-World Treatment Patterns and Survival of Patients with BRAF V600-Mutated Metastatic Non-Small Cell Lung Cancer

Ongoing scientific efforts to define the mechanisms driving cancer cell proliferation and survival have led to the classification of non-small cell lung cancer (NSCLC) by the presence of specific genetic aberrations, some of which render tumors actionable for targeted therapy [1 –5]. One of the oncogenic drivers under study in NSCLC is mutated BRAF (v-RAF murine sarcoma viral oncogene homolog B), a serine-threonine kinase belonging to the RAF kinase family that directly interacts with the MEK-ERK signaling cascade.

Source: Lung Cancer - December 7, 2018 Category: Cancer & Oncology Authors: Leora Horn, Joshua Bauml, Patrick M. Forde, Keith L. Davis, Nathaniel J. Myall, Medha Sasane, Anand Dalal, Ken Culver, Antoinette J. Wozniak, Christina S. Baik, Alex Mutebi, Pingkuan Zhang, Heather A. Wakelee, Bruce E. Johnson Source Type: research